Coya Therapeutics, Inc.
COYANext catalyst
COYA 302
Amyotrophic Lateral Sclerosis (ALS)
Get an email about COYA's next catalysts
Track Coya Therapeutics (COYA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
COYA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.35 | FQ end Sep/2026 | Call: tbd
COYA 302 Phase 3 Est. Readout (ALSTARS)
Estimated primary completion for COYA 302 trial (NCT07161999) in Amyotrophic Lateral Sclerosis (ALS). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
COYA 302 | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
Frequently asked questions
What is in Coya Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Coya Therapeutics, Inc.'s (COYA) pipeline across Phase 3. Its lead program is COYA 302 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Coya Therapeutics, Inc.'s next FDA catalyst?→
Coya Therapeutics, Inc.'s (COYA) next tracked catalyst is a Phase 3 readout expected April 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track COYA biotech catalysts?→
Add COYA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Coya Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.